260 related articles for article (PubMed ID: 35849084)
1. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
[TBL] [Abstract][Full Text] [Related]
2. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure.
Heineke J; Auger-Messier M; Xu J; Sargent M; York A; Welle S; Molkentin JD
Circulation; 2010 Jan; 121(3):419-25. PubMed ID: 20065166
[TBL] [Abstract][Full Text] [Related]
4. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
5. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
6. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.
Smith RC; Lin BK
Curr Opin Support Palliat Care; 2013 Dec; 7(4):352-60. PubMed ID: 24157714
[TBL] [Abstract][Full Text] [Related]
7. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
8. Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro.
Ge Z; Liu D; Shang Y; Li Y; Chen SZ
J Nat Med; 2020 Sep; 74(4):741-749. PubMed ID: 32601830
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia.
Peng B; Yang Y; Wu Z; Tan R; Pham TT; Yeo EYM; Pirisinu M; Jayasinghe MK; Pham TC; Liang K; Shyh-Chang N; Le MTN
Mol Ther; 2023 May; 31(5):1418-1436. PubMed ID: 37016578
[TBL] [Abstract][Full Text] [Related]
10. The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.
Lan XQ; Deng CJ; Wang QQ; Zhao LM; Jiao BW; Xiang Y
Gen Comp Endocrinol; 2024 Jul; 353():114513. PubMed ID: 38604437
[TBL] [Abstract][Full Text] [Related]
11. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.
Currow DC; Abernethy AP
Future Oncol; 2014 Apr; 10(5):789-802. PubMed ID: 24472001
[TBL] [Abstract][Full Text] [Related]
12. The possible role of myostatin in skeletal muscle atrophy and cachexia.
Jespersen J; Kjaer M; Schjerling P
Scand J Med Sci Sports; 2006 Apr; 16(2):74-82. PubMed ID: 16533345
[TBL] [Abstract][Full Text] [Related]
13. Anamorelin for cancer cachexia.
Nishie K; Sato S; Hanaoka M
Drugs Today (Barc); 2022 Mar; 58(3):97-104. PubMed ID: 35274629
[TBL] [Abstract][Full Text] [Related]
14. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.
Zhou L; Zhang T; Shao W; Lu R; Wang L; Liu H; Jiang B; Li S; Zhuo H; Wang S; Li Q; Huang C; Lin D
Skelet Muscle; 2021 Jul; 11(1):17. PubMed ID: 34229732
[TBL] [Abstract][Full Text] [Related]
15. Identification of the minimum region of flatfish myostatin propeptide (Pep45-65) for myostatin inhibition and its potential to enhance muscle growth and performance in animals.
Kim JH; Kim JH; Sutikno LA; Lee SB; Jin DH; Hong YK; Kim YS; Jin HJ
PLoS One; 2019; 14(4):e0215298. PubMed ID: 30998775
[TBL] [Abstract][Full Text] [Related]
16. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
Fonseca GWPD; von Haehling S
Expert Opin Pharmacother; 2021 May; 22(7):889-895. PubMed ID: 33491505
[TBL] [Abstract][Full Text] [Related]
17. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Zhang H; Garcia JM
Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
[TBL] [Abstract][Full Text] [Related]
19. [Role of Activin A and Myostatin in cancer cachexia].
Thissen JP; Loumaye A
Ann Endocrinol (Paris); 2013 May; 74(2):79-81. PubMed ID: 23566617
[TBL] [Abstract][Full Text] [Related]
20. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
